Sep 19, 2015

Bevacizumab Triplet Improves Survival in Mesothelioma


Bevacizumab Triplet Improves Survival in Mesothelioma


Snip of article: "...Adding bevacizumab (Avastin) to a standard chemotherapy doublet reduced the risk of death by 24% and disease progression by 39% in patients with malignant pleural mesothelioma (MPM), according to results from the phase II/III MAPS trial presented at the 2015 World Conference on Lung Cancer1...."


Article Reference: www.onclive.com
Tags: Bevacizumab Triplet, bevacizumab (Avastin), malignant pleural mesothelioma (MPM),

No comments:

Post a Comment